Level Biotechnology (3118) — Cash Flow Reinvestment Rate
Level Biotechnology (3118) has a Cash Flow Reinvestment Rate of 0.80x as of September 2025, reinvesting NT$9.45 Million (capex NT$4.44 Million plus investments NT$-5.01 Million) from operating cash flow of NT$11.81 Million. Check 3118 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Level Biotechnology Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for Level Biotechnology across 8 annual periods. Explore Level Biotechnology cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Level Biotechnology (2017–2024)
Year-by-year capital reinvestment analysis for Level Biotechnology. For live market cap and broader valuation context, see Level Biotechnology market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.57x | NT$228.80 Million | NT$64.10 Million | NT$223.68 Million | ▲ +1249.9% |
| 2023 | 0.26x | NT$18.57 Million | NT$70.21 Million | NT$7.67 Million | ▲ +1.7% |
| 2022 | 0.26x | NT$16.93 Million | NT$65.07 Million | NT$6.74 Million | ▲ +317.3% |
| 2021 | 0.06x | NT$9.72 Million | NT$155.95 Million | NT$9.15 Million | ▲ +67.0% |
| 2020 | 0.04x | NT$3.11 Million | NT$83.23 Million | NT$2.54 Million | ▲ +36.0% |
| 2019 | 0.03x | NT$2.99 Million | NT$109.02 Million | NT$2.43 Million | ▼ -76.1% |
| 2018 | 0.11x | NT$3.08 Million | NT$26.77 Million | NT$2.51 Million | ▼ -78.3% |
| 2017 | 0.53x | NT$37.79 Million | NT$71.29 Million | NT$10.83 Million | — |